Esperion Therapeutics: Little Upside Potential In Their Earlier Generation Drug
Esperion Therapeutics has two approved LDL-C lowering therapies, Nexletol and Nexlizet, but lacks a strong pipeline for future growth.
Is Merck Stock a Buy?
It's been a rough start to 2025 for Merck (NYSE: MRK) shareholders following a less-than-stellar fourth-quarter earnings ...
ROSEN, NATIONAL INVESTOR COUNSEL, Encourages Merck & Co., Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action - MRK
Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Merck & Co., Inc. (NYSE: MRK) between February 3, 2022 and February 3, 2025, both dates inclusive (the "Class ...
Scripps Research gives old anti-malaria drug better staying power
A new clinical trial from Scripps Research hopes to make significant gains in the global fight against malaria by making a drug that has been around since the 1970s last longer. Working with a ...
Merck & Co. Inc. stock outperforms competitors on strong trading day
Shares of Merck & Co. Inc. MRK rallied 2.08% to $89.50 Friday, on what proved to be an all-around rough trading session for ...
Why Merck (MRK) is a Great Dividend Stock Right Now
Dividends are one of the best benefits to being a shareholder, but finding a great dividend stock is no easy task. Does Merck (MRK) have what it takes? Let's find out.